← Back to Search

Monoclonal Antibodies

APR003 for Colorectal Cancer

Phase 1
Waitlist Available
Research Sponsored by Apros Therapeutics, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to three years
Awards & highlights

Study Summary

This trial is testing a new drug, APR003, to see if it is effective in treating advanced colorectal cancer that has spread to the liver.

Eligible Conditions
  • Colorectal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measure
Secondary outcome measures

Trial Design

1Treatment groups
Experimental Treatment
Group I: APR003 Dose EscalationExperimental Treatment1 Intervention
This portion of the study will evaluate the safety and pharmacokinetics of a range of APR003 doses administered once a week for 21 days in subjects with advance colorectal cancer (CRC) with metastases to the liver and to determine the RP2D.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
APR003
2021
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Apros Therapeutics, IncLead Sponsor
1 Previous Clinical Trials
42 Total Patients Enrolled
Aaron Weitzman, MDStudy DirectorApros Therapeutics, Inc
1 Previous Clinical Trials
Trinh LeStudy DirectorApros Therapeutics, Inc
1 Previous Clinical Trials
153 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can APR003 be administered to patients with no adverse effects?

"Owing to the limited research into its efficacy and safety, APR003 is classified as a Phase 1 trial and thus received a score of 1."

Answered by AI

How many participants may join this clinical study?

"Affirmative, the information hosted on clinicaltrials.gov reveals that this experiment is currently recruiting participants. This trial was originally published on January 20th 2021 and has been updated as recently as April 29th 2021. A total of 36 people are required to be recruited from 4 distinct sites."

Answered by AI

Are there opportunities for enrolment in this experiment?

"Clinicialtrials.gov reports that this clinical trial, which was initially published on the 20th of January 2021, is currently in pursuit of volunteers for participation. The last time it underwent editing was on April 29th 2021."

Answered by AI

Is there a way I can join this research effort?

"This experiment seeks to enlist 36 colorectal cancer patients aged between 18 and 75 who meet the following eligibility conditions: Eastern Cooperative Oncology Group (ECOG) status of 0 or 1, already experienced relapse/persistence with two SOC treatments for locally advanced or metastatic illness, prior exposure to irinotecan-based therapy as well as targeted antibody treatment for metastasis, non-surgically resectable malady."

Answered by AI

How many locales are carrying out this scientific experiment?

"Patients are being enrolled for the trial at NEXT Oncology - Austin in Austin, AdventHealth Orlando in Orlando, and Carolina BioOncology Institute Cancer Research Clinic in Huntersville. In addition, there is recruitment taking place from 4 other sites."

Answered by AI

Does this clinical study have a minimum age limit, and if so, what is it?

"This medical trial has an age constraint, only accepting patients who are more than 18 years old but below 75."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
2021. "A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04645797.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top